We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+20.42%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$380M
Cap. Flow
-$843M
Cap. Flow %
-27.17%
Top 10 Hldgs %
37.76%
Holding
82
New
16
Increased
13
Reduced
14
Closed
12

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$50.7M
2
CGON icon
CG Oncology
CGON
+$46.2M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$42.3M
4
LEGN icon
Legend Biotech
LEGN
+$41.1M
5
TMDX icon
Transmedics
TMDX
+$40.9M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$41.8M
2
LNTH icon
Lantheus
LNTH
+$30.7M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$30.6M
4
KROS icon
Keros Therapeutics
KROS
+$22.6M
5
AMGN icon
Amgen
AMGN
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 57.18%
2 Miscellaneous 42.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
26
Kiniksa Pharmaceuticals
KNSA
$6.09B
$27.5M 0.89%
+1,392,716
New +$27.2M
TMO icon
27
Thermo Fisher Scientific
TMO
$230B
$27.4M 0.88%
47,149
-28,600
-38% -$16M
RGEN icon
28
Repligen
RGEN
$9.95B
$26.3M 0.85%
142,836
+40,138
+39% +$7.64M
NVRO
29
DELISTED
NEVRO CORP.
NVRO
$25.7M 0.83%
1,776,368
– –
INSP icon
30
Inspire Medical Systems
INSP
$1.78B
$21.8M 0.7%
101,492
-83,166
-45% -$16.3M
CGEM icon
31
Cullinan Oncology
CGEM
$1.4B
$21.1M 0.68%
1,240,865
– –
TRML
32
DELISTED
Tourmaline Bio
TRML
$20.8M 0.67%
906,820
– –
LXEO icon
33
Lexeo Therapeutics
LXEO
$399M
$20.7M 0.67%
+1,322,277
New +$20.7M
SYRE icon
34
Spyre Therapeutics
SYRE
$7.97B
$19.5M 0.63%
515,000
– –
BMRN icon
35
BioMarin Pharmaceuticals
BMRN
$12.5B
$19.1M 0.62%
+218,896
New +$19.6M
GPCR icon
36
Structure Therapeutics
GPCR
$3.38B
$18.7M 0.6%
435,823
+155,665
+56% +$6.56M
BCRX icon
37
BioCryst Pharmaceuticals
BCRX
$2.51B
$17.2M 0.55%
3,379,577
-2,338,900
-41% -$13.2M
ITOS
38
DELISTED
iTeos Therapeutics
ITOS
$15.9M 0.51%
+1,162,374
New +$12.7M
MLYS icon
39
Mineralys Therapeutics
MLYS
$2.26B
$14.8M 0.48%
1,147,154
-876,746
-43% -$10.8M
ALEC icon
40
Alector
ALEC
$261M
$14.3M 0.46%
2,380,704
-943,604
-28% -$6.17M
ARQT icon
41
Arcutis Biotherapeutics
ARQT
$2.99B
$12.9M 0.42%
+1,300,000
New +$9.7M
ELEV
42
DELISTED
Elevation Oncology
ELEV
$12.2M 0.39%
+2,377,647
New +$7.7M
BBIO icon
43
BridgeBio Pharma
BBIO
$15B
$10.7M 0.34%
+344,827
New +$11.7M
IOVA icon
44
Iovance Biotherapeutics
IOVA
$3.63B
$9.78M 0.32%
+660,022
New +$7.68M
DCPH
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$9.59M 0.31%
609,643
-559,847
-48% -$8.62M
OLMA icon
46
Olema Pharmaceuticals
OLMA
$899M
$7.97M 0.26%
+704,344
New +$9.09M
LUNG icon
47
Pulmonx
LUNG
$102M
$6.98M 0.22%
752,541
-35,413
-4% -$415K
DBVT
48
DBV Technologies
DBVT
$851M
$5.93M 0.19%
784,329
– –
OM icon
49
Outset Medical
OM
$74.1M
$5.33M 0.17%
160,028
– –
ADPT icon
50
Adaptive Biotechnologies
ADPT
$4.02B
$4.36M 0.14%
1,357,490
– –
1
2
3

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q1 2024 Portfolio in Review

As of Q1 2024, Braidwell held 82 positions worth $3.1B, up 14% from $2.72B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $843M in Q1 2024, closing 12 positions and reducing 14 holdings. Its most notable exit was Immunocore, an estimated $41.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 49% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in CG Oncology worth $49.6M.

  • Braidwell's largest Q1 2024 buy was CG Oncology: 1,130,235 shares worth $49.6M.
  • Braidwell added most to Apogee Therapeutics in Q1 2024, an estimated $50.7M increase.
  • Braidwell's biggest Q1 2024 reduction was Day One Biopharmaceuticals, cutting an estimated $30.6M.
  • Braidwell fully exited Immunocore in Q1 2024, selling an estimated $41.8M.
  • Braidwell's ten largest holdings make up 38% of its $3.1B portfolio in Q1 2024.
  • Braidwell opened 16 new positions and closed 12 in Q1 2024.
  • Braidwell's portfolio value rose 14% quarter-over-quarter to $3.1B.

Based on Braidwell's 13F filing for Q1 2024, filed 15 May 2024.